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Abstract
Preoperative hypoalbuminemia is known to be associated with post-
operative morbidity and mortality, as well as with poor survival after 
gastrointestinal cancer surgery. However, limited data exist regarding 
the prognostic significance of hypoalbuminemia in patients with peri-
toneal metastases undergoing cytoreductive surgery, combined with 
perioperative intraperitoneal chemotherapy. We performed a system-
atic literature review of the previously published studies addressing 
the potential association between preoperative albumin levels and 
overall surgical outcomes after the performance of cytoreductive sur-
gery and perioperative intraperitoneal chemotherapy for peritoneal 
surface malignancies. Our research yielded a total of nine retrospec-
tive studies which met our inclusion criteria, and despite their hetero-
geneity; and we can conclude that preoperatively low albumin levels 
are associated with greater likelihood of overall and major morbidity, 
as well as less favorable oncological outcome after the performance 
of cytoreductive surgery and perioperative intraperitoneal chemo-
therapy.
Keywords: Albumin; Cytoreductive surgery; Intraperitoneal chemo-
therapy; HIPEC; Nutrition; Cancer; Peritoneal malignancy
Introduction
Cytoreductive surgery (CRS) combined with perioperative 
intraperitoneal chemotherapy (PIC) is considered a promising 
treatment option in appropriately selected patients with peri-
toneal metastatic disease and primary peritoneal malignan-
cies [1, 2]. CRS aims to achieve complete macroscopic re-
moval of the visible cancerous deposits within the abdominal 
cavity (complete cytoreduction), while the administration of 
PIC is used to achieve microscopic disease clearance, target-
ing the intra-abdominally circulating cancer cells and cancer-
ous lesions of few cell lines depth [3]. Due to the nature of the 
operation, which usually requires multi-visceral resections, 
and the adverse effects of the intraperitoneal chemotherapy, 
this combined procedure carries considerable postoperative 
morbidity and mortality, even in high-volume centers [4]. In 
order to improve the postoperative outcome and the onco-
logical benefit of this complex procedure, several key areas 
for improvement have been identified over the last years. 
These include the recognition of the role mentorship and sen-
ior supervision to overcome the procedure’s steep learning 
curve [5-7], the rationalization of patient selection criteria for 
CRS and PIC [8, 9], the improvement of imaging techniques 
used to guide the operative decision-making [10], along with 
efforts to reduce the toxicity of the intraperitoneal chemo-
therapy and optimize the postoperative care of these patients 
[11-13].
Interestingly, there is a relative lack of studies focusing 
on the impact of malnutrition on postoperative morbidity and 
mortality, as well as the survival after CRS and PIC. The lat-
ter is of great importance given the widely accepted value of 
optimizing the patients’ nutrition status prior to any major 
abdominal procedure, which has been shown to be inversely 
correlated with overall complication rates and length of hos-
pitalization [14, 15]. Moreover, particularly in patients under-
going major abdominal oncological operation, preoperative 
malnutrition has been strongly associated with poorer survival 
[16, 17]. Therefore, it is reasonable to assume that preopera-
tive detection of patients at nutritional risk and enhanced nu-
tritional support could help to achieve a reduction of morbid-
ity and mortality after CRS and PIC, and potentially improve 
the oncological outcomes of the procedure. Under this notion, 
the preoperative evaluation of widely available malnutrition 
markers, with serum albumin being the traditional labora-
tory reference test [18] could be of value in the planning of 
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a holistic treatment plan. To address this question, we have 
performed a systematic review of the literature of the stud-
ies examining an association of preoperative albumin levels 
with the occurrence of postoperative morbidity and mortality, 
as well as survival after CRS and PIC for peritoneal surface 
malignancies.
Methods
We performed a systematic review of the studies indexed in Pub-
Med database until August 2020, using the search terms (“al-
bumin” AND “cytoreductive surgery”) and (“albumin” AND 
“intraperitoneal chemotherapy”), in accordance to PRISMA 
guidelines. Citations of articles retrieved at the initial literature 
search were manually searched to identify further relevant stud-
ies meeting the purpose and selection criteria of this systematic 
review. We excluded studies referring to pediatric population, as 
well as studies where CRS was performed but not followed by 
PIC. Also, we excluded studies published in other than English 
language as well as case reports and case series.
Results
A total of nine studies [19-27], all retrospective in nature, met 
our inclusion criteria (Fig. 1). Six out of the nine included 
studies included patients with peritoneal disease arising from 
two or more primary origins [19-23, 25], while two studies 
used as study population patients of older age groups, who had 
undergone CRS and PIC [20, 25]. Despite the significant het-
erogeneity in terms of primary malignancies, extent of perito-
neal disease and differences in patient selection and treatment 
protocols, the main two clinical questions of our systematic 
review, association of albumin levels with postoperative mor-
bidity/mortality and survival after CRS and PIC, could be an-
swered in a clear manner.
With respect to the potential value of preoperative serum 
albumin as a prognostic factor of survival after CRS and PIC, 
seven of the studies addressed this point [19, 21, 23-27]. In 
Figure 1. Flowchart of the systematic review.
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five of those studies, preoperatively lower albumin levels, as 
defined in each study by the authors, were strongly associated 
with poorer survival rates [19, 21, 23, 24, 26, 27], while Votan-
opoulos and co-workers [25] did not demonstrate any relevant 
prognostic significance of preoperative albumin in their cohort 
of patients after CRS and PIC. The key features of the included 
studies (study population, origin of peritoneal disease, postop-
erative morbidity and mortality, as well as survival outcomes) 
and information regarding the correlations of preoperative 
serum albumin levels with the operative and oncological out-
come are presented in detailed manner in Table 1 [19-27].
Discussion
Serum albumin has traditionally been considered as a classi-
cal laboratory marker reflecting surgical patients’ nutritional 
status, despite the fact that its levels can be influenced by a 
variety of factors (i.e., acute illness, chronic inflammatory re-
sponse, and liver pathologies, etc) [28, 29]. However, the low 
cost of the relevant laboratory essays and the wide availability 
of this examination as a basic paraclinical parameter, has led 
to its disseminated use as a nutritional marker in the general 
surgery practice [30]. The latter is of great importance in surgi-
cal oncology, as apart from the surgical stress and the subse-
quent catabolic cascade, the operable patients can frequently 
be in preclinical stages of cancer-related cachexia with evolv-
ing skeletal muscle depletion [31, 32]. Therefore, preoperative 
serum albumin levels have been highlighted by numerous pre-
vious studies in the field of surgical oncology as an important 
marker of perioperative morbidity and survival after surgery 
for gastrointestinal malignancies [33, 34].
Taking into consideration the greater magnitude of cancer 
burden in cases of peritoneal metastatic disease, which very fre-
quently can present with symptoms of gastrointestinal intoler-
ance and poor oral intake, the importance of adequate nutrition-
al status is a key feature for the success of a major procedure 
as CRS and PIC. Previous studies in patients with peritoneal 
malignancy undergoing CRS and PIC have clearly demonstrat-
ed the postoperative occurrence of prolonged ileus, which pro-
hibits early oral nutrition; even early enteral nutrition has been 
shown not to be well tolerated in the immediate postoperative 
phase, requiring frequently the postoperative administration of 
parenteral nutrition [35]. Furthermore, the major stress assault 
from this extensive surgical procedure results in a significant 
drop of postoperative serum albumin levels, indicating the ex-
tent of the post-surgical inflammatory response and the initia-
tion of a catabolic response [36]. As a result, it is evident that 
patients scheduled for CRS and PIC need to be nutritionally 
optimized before embarking for surgery with a structured spe-
cialist nutritional assessment and supplementation as required, 
and serum albumin should be included as a baseline laboratory 
marker in the nutrition enhancement pathway.
Although the above-mentioned seem reasonable, very 
few studies [19-27] have previously assessed the usefulness of 
preoperative albumin levels as a marker of post-CRS and PIC 
morbidity and/or survival outcomes. Our study is the first in the 
literature to review in a systematic manner the available evi-
dence of this topic. Despite their heterogeneity with regards to 
primary cancer origin, extent of peritoneal metastatic disease 
and different albumin cut-off values, the overall qualitative 
conclusion from our review study is that preoperatively low 
albumin levels are associated with an increase in postoperative 
morbidity, especially grade III/IV complications, and have a 
prognostic value as a marker of survival post CRS and PIC. As 
presented in the Table 1 summarizing the relevant findings of 
the included studies, there is no universal agreement to define a 
cut-off value of serum albumin value as a predictor of expected 
postoperative morbidity and/or mortality. However, the major-
ity of included studies define hypoalbuminemia when serum 
albumin value was lower than 3.5 g/dL, and therefore this val-
ue potentially could be a starting point for future prospectively 
conducted studies, as a target to reach before proceeding with 
CRS and PIC. Considering the known limitations of albumin 
as the sole laboratory marker of nutritional status, effort should 
be made towards the formation of nutritional risk stratifica-
tion scoring systems, combining laboratory markers (albumin, 
pre-albumin, electrolytes and minerals, etc.) with anthropo-
metric nutritional assessments (body mass index (BMI), skin-
fold thickness, mid-arm muscle circumference, etc.), existing 
validated nutritional risk tools (MUST, SNAQ, MNA-SF, etc.) 
and perhaps imaging techniques, such as estimation of skeletal 
mass via the standard preoperative computed tomography. We 
believe that preoperative enhanced nutrition should be consid-
ered as a standard parameter of the preoperative assessment 
and patient optimization before CRS with PIC, and serum al-
bumin levels should be assessed as a standard parameter in the 
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study are available within the article.
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